Gilabert J, Estellés A, Grancha S, España F, Aznar J
Maternal Center, La Fe' University Hospital, Valencia, Spain.
Hum Reprod. 1995 Dec;10 Suppl 2:121-31. doi: 10.1093/humrep/10.suppl_2.121.
Here we summarize the recent progress in research on the role of the fibrinolytic system in reproduction, with a special emphasis on the role of the plasminogen activator inhibitors in fetal development. Trophoblasts produce fibrinolytic proteins that can promote normal implantation and regulate blood flow to the fetus and placenta throughout pregnancy. Normal pregnancy is associated with a hypofibrinolytic state that is fundamentally caused by an increase in plasminogen activator inhibitors types 1 and 2. In pre-eclampsia, a fibrinolytic failure, resulting from an increase in plasma and placental concentrations of plasminogen activator inhibitor-1, was observed. The localized elevated concentrations of placenta plasminogen activator inhibitor-1 protein and mRNA observed in pre-eclamptic patients would be expected to foster the deposition of fibrin and thus play a role in the complications associated with this disease. The decreased plasminogen activator inhibitor-2 concentrations in placenta and plasma from intrauterine fetal growth retardation pregnancies and the positive correlation between plasma/placenta plasminogen activator inhibitor-2 concentration and birthweight suggest that this inhibitor could be considered an adequate marker of placental function.
在此，我们总结了近期关于纤溶系统在生殖过程中作用的研究进展，特别强调了纤溶酶原激活物抑制剂在胎儿发育中的作用。滋养层细胞产生的纤溶蛋白可促进正常着床，并在整个孕期调节流向胎儿和胎盘的血流。正常妊娠与低纤溶状态相关，这主要是由1型和2型纤溶酶原激活物抑制剂增加所致。在子痫前期，观察到由于血浆和胎盘纤溶酶原激活物抑制剂-1浓度升高导致纤溶功能衰竭。子痫前期患者胎盘纤溶酶原激活物抑制剂-1蛋白和mRNA的局部浓度升高，预计会促进纤维蛋白沉积，从而在该疾病相关并发症中发挥作用。宫内胎儿生长受限妊娠的胎盘和血浆中纤溶酶原激活物抑制剂-2浓度降低，以及血浆/胎盘纤溶酶原激活物抑制剂-2浓度与出生体重之间的正相关表明，该抑制剂可被视为胎盘功能的合适标志物。
